FATE Stock Recent News

Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications

The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.

–   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each v

FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.

Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago.

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesti

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: